Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexucabtagene Autoleucel as Consolidation in R/R and Newly Diagnosed B-cell ALL
NCT06287229Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year and Event-Free Survival at 18 months. Started Jul 2024; status: recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06287229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287229.